T-cell-based breast cancer immunotherapy

Karolina Pilipow; Abbass Darwich; Agnese Losurdo

doi:10.1016/j.semcancer.2020.05.019

T-cell-based breast cancer immunotherapy

Karolina Pilipow, Abbass Darwich, Agnese Losurdo

Istituto Clinico Humanitas

Research output: Contribution to journal › Review article › peer-review

Abstract

Cancer immunotherapy has witnessed a new renaissance with the advent of immune checkpoint inhibitors, which reactivate T cells and foster endogenous anti-tumor responses. The excellent results of immunotherapy in the field of melanoma, renal cancer, lung cancer, and other cancer types that have traditionally been known to be immunogenic, rekindled the interest of the oncology community in extending the benefits to all cancers including breast cancer (BC). In this review, we highlight the current state of using T cells as both markers for clinical practice and therapeutic options for BC.

Original language	English
Journal	Seminars in Cancer Biology
DOIs	https://doi.org/10.1016/j.semcancer.2020.05.019
Publication status	E-pub ahead of print - May 31 2020

Access to Document

10.1016/j.semcancer.2020.05.019

Fingerprint Dive into the research topics of 'T-cell-based breast cancer immunotherapy'. Together they form a unique fingerprint.

Cite this

@article{12ba16a8a2fd48b4bc5961022f9eeb4c,

title = "T-cell-based breast cancer immunotherapy",

abstract = "Cancer immunotherapy has witnessed a new renaissance with the advent of immune checkpoint inhibitors, which reactivate T cells and foster endogenous anti-tumor responses. The excellent results of immunotherapy in the field of melanoma, renal cancer, lung cancer, and other cancer types that have traditionally been known to be immunogenic, rekindled the interest of the oncology community in extending the benefits to all cancers including breast cancer (BC). In this review, we highlight the current state of using T cells as both markers for clinical practice and therapeutic options for BC.",

author = "Karolina Pilipow and Abbass Darwich and Agnese Losurdo",

year = "2020",

month = may,

day = "31",

doi = "10.1016/j.semcancer.2020.05.019",

language = "English",

journal = "Seminars in Cancer Biology",

issn = "1044-579X",

publisher = "Academic Press",

}

TY - JOUR

T1 - T-cell-based breast cancer immunotherapy

AU - Pilipow, Karolina

AU - Darwich, Abbass

AU - Losurdo, Agnese

PY - 2020/5/31

Y1 - 2020/5/31

N2 - Cancer immunotherapy has witnessed a new renaissance with the advent of immune checkpoint inhibitors, which reactivate T cells and foster endogenous anti-tumor responses. The excellent results of immunotherapy in the field of melanoma, renal cancer, lung cancer, and other cancer types that have traditionally been known to be immunogenic, rekindled the interest of the oncology community in extending the benefits to all cancers including breast cancer (BC). In this review, we highlight the current state of using T cells as both markers for clinical practice and therapeutic options for BC.

AB - Cancer immunotherapy has witnessed a new renaissance with the advent of immune checkpoint inhibitors, which reactivate T cells and foster endogenous anti-tumor responses. The excellent results of immunotherapy in the field of melanoma, renal cancer, lung cancer, and other cancer types that have traditionally been known to be immunogenic, rekindled the interest of the oncology community in extending the benefits to all cancers including breast cancer (BC). In this review, we highlight the current state of using T cells as both markers for clinical practice and therapeutic options for BC.

U2 - 10.1016/j.semcancer.2020.05.019

DO - 10.1016/j.semcancer.2020.05.019

M3 - Review article

C2 - 32492452

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

ER -